newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma to Participate in Upcoming Investor Conferences

  • Immix Biopharma, Inc. will present & host investor meetings at the Leerink Partners 2026 Global Healthcare Conference (March 8-11, 2026, Miami Beach, FL) & the Citizens Life Sciences Conference (March 10-11, 2026, Miami Beach, FL).
  • Company management will conduct one-on-one meetings, requiring interested investors to contact their Leerink or Citizens representatives for scheduling.
  • Replays of presentations will be posted on the Immix website under the Investors section.
  • ImmixBio is the global leader in relapsed/refractory AL Amyloidosis, a disease where toxic light chains cause organ failure.
  • The company's lead candidate is NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy featuring a "digital filter" to prevent non-specific activation.
  • NXC-201 is currently being evaluated in the multi-center NEXICART-2 study (NCT06097832) with a registrational design.
  • NXC-201 holds Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy status from the US FDA, & Orphan Drug Designation from the FDA & EMA.